课题基金 / 基金详情

项目摘要

项目成果

John R. Hawse的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):骨质疏松症是一种骨骼疾病,影响全球近三分之一的女性,超过55%的美国人,仅在美国每年的医疗保健费用就超过190亿美元。自从我们实验室发现TGF β诱导早期基因-1(TIEG)以来,我们已经证明小鼠TIEG表达的缺失导致成骨细胞和破骨细胞的多种缺陷,并赋予仅影响雌性动物的性别特异性骨质减少表型。最近,TIEG已被鉴定为仅有的几个基因之一,其改变的表达水平或等位基因变异与人类骨量减少和骨质疏松症相关。在过去的资助期间,我们已经表明TIEG表达对于骨中的雌激素信号传导是必不可少的,并且已经确定了TIEG在介导骨骼中的经典Wnt信号传导中的新作用。这些观察结果具有重要意义,因为雌激素仍然是男性和女性骨稳态的最重要调节剂之一,并且因为Wnt信号传导对于正常骨发育和维持至关重要。由于这些原因,了解骨骼中这些通路的调节至关重要。在该提议中,我们提出了TIEG通过双重机制增强Wnt信号传导途径的证据,由此它直接抑制硬化蛋白的表达并充当β-连环蛋白的转录共激活剂。此外,我们的数据表明,TIEG作为骨中雌激素和经典Wnt通路之间的直接联系。基于这些观察结果,我们的中心假设是TIEG是经典Wnt信号传导的重要组成部分,并在调节骨骼中雌激素和Wnt通路之间的串扰中发挥核心作用。为了检验这一假设,提出了以下具体目的:1):表征TIEG对硬化蛋白基因表达的调节,并确定其对TIEG敲除小鼠的观察到的骨质减少表型的贡献; 2):表征TIEG通过β-连环蛋白的共活化增强经典Wnt信号传导的能力;和3)确定TIEG KO小鼠的性别特异性(仅雌性)骨质减少表型是否由骨中雌激素和经典Wnt信号传导途径之间的缺陷性串扰引起。为了解决这些具体目标,我们将采用体外方法来鉴定TIEG抑制骨细胞中硬化蛋白表达和增强成骨细胞中β-连环蛋白功能的分子机制。此外,我们将利用多种体内模型和方法来剖析TIEG在调节经典Wnt通路活性和骨骼中雌激素与Wnt信号传导之间的串扰中的作用。考虑到雌激素和Wnt信号传导在骨中的基本作用,以及目前针对这些途径治疗骨质疏松症,了解TIEG在调节这两种途径中的作用至关重要。因此,预计完成拟议的研究将为开发治疗这种使人衰弱的疾病的新策略提供重要的知识。
英文摘要
DESCRIPTION (provided by applicant): Osteoporosis is a bone disease affecting nearly 1 in 3 women worldwide and over 55% of all Americans resulting in health care costs exceeding 19 billion dollars annually in the United States alone. Since the discovery of the TGFß inducible early gene-1 (TIEG) by our laboratory, we have demonstrated that loss of TIEG expression in mice results in multiple defects in osteoblasts and osteoclasts and confers a gender specific osteopenic phenotype affecting only female animals. Recently, TIEG has been identified as one of only a few genes whose altered expression levels or allelelic variations associate with decreased bone mass and osteoporosis in humans. During the past funding period, we have shown that TIEG expression is essential for estrogen signaling in bone and have identified a novel role for TIEG in mediating canonical Wnt signaling in the skeleton. These observations are of significant interest since estrogen remains one of the most important regulators of bone homeostasis in both men and women and since Wnt signaling is essential for normal bone development and maintenance. For these reasons, it is crucial to understand the regulation of these pathways in the skeleton. In this proposal, we present evidence that TIEG enhances the Wnt signaling pathway via dual mechanisms whereby it directly suppresses the expression of sclerostin and serves as a transcriptional co- activator for ß-catenin. Furthermore, our data suggest that TIEG serves as a direct link between the estrogen and canonical Wnt pathways in bone. Based on these observations, our central hypothesis is that TIEG is a crucial component of canonical Wnt signaling and serves a central role in regulating cross-talk between the estrogen and Wnt pathways in the skeleton. In order to test this hypothesis, the following Specific Aims are proposed: 1): Characterize the regulation of sclerostin gene expression by TIEG and determine its contribution to the observed osteopenic phenotype of TIEG knockout mice; 2): Characterize the ability of TIEG to enhance canonical Wnt signaling through co-activation of ß-catenin; and 3) Determine if the gender specific (female only) osteopenic phenotype of TIEG KO mice results from defective cross-talk between the estrogen and canonical Wnt signaling pathways in bone. To address these Specific Aims, we will employ in vitro approaches to identify the molecular mechanisms by which TIEG suppresses sclerostin expression in osteocytes and enhances ß-catenin function in osteoblasts. Additionally, we will utilize multiple in vivo models and approaches to dissect the role of TIEG in regulating canonical Wnt pathway activity and cross-talk between estrogen and Wnt signaling in the skeleton. Considering the fundamental roles of estrogen and Wnt signaling in bone, as well as the present day targeting of these pathways for the treatment of osteoporosis, it is essential to understand the role of TIEG in regulating these two pathways. Completion of the proposed studies is therefore expected to provide significant knowledge with regard to developing novel strategies to treat this debilitating disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC
  • 批准号:
    10540349
  • 项目类别:
  • 资助金额:
    $50.63万
  • 财政年份:
    2021
  • 负责人:
    John R. Hawse
  • 依托单位:
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC
  • 批准号:
    10116790
  • 项目类别:
  • 资助金额:
    $47.69万
  • 财政年份:
    2021
  • 负责人:
    John R. Hawse
  • 依托单位:
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC
  • 批准号:
    10320463
  • 项目类别:
  • 资助金额:
    $49.96万
  • 财政年份:
    2021
  • 负责人:
    John R. Hawse
  • 依托单位:
Role of sex steroids in female TIEG-null mouse bone loss
  • 批准号:
    7109536
  • 项目类别:
  • 资助金额:
    $4.88万
  • 财政年份:
    2006
  • 负责人:
    John R. Hawse
  • 依托单位:
海外基金